retatrutide triple agonist glp-1 gip glucagon phase 2 nejm 2023 just posted the biggest weight-loss numbers ever recorded for a drug — 28.3% (≈70 lb) average in 3, with 45% of people hitting 30%+ loss, territory once reserved for bariatric From Obesity to Metabolic Health:

| Curex Kaiser Permanente covers Vyvanse on its closed formulary via Kaiser pharmacies generic lisdexamfetamine preferred, brand non-preferred

Pentadecapeptide BPC 157 reduces bleeding and thrombocytopenia after amputation in rats

obesity coverage is still hit-or-miss

At Formation, peptide therapy and PRP treatments are administered by Jeff Atlas, PA-C, a physician assistant with a background in orthopedics who brings hands-on expertise in musculoskeletal health, regenerative techniques, and injection precision to every session

Additional findings Beyond weight loss, the Phase 2 trial revealed several additional benefits